[Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
125 patients in the early stages of Parkinson's syndrome were randomized and subjected to prearranged treatment adaptation period. Subsequently they were treated with either a mean dosage of 444 mg levodopa and benserazide (47 patients) or a combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine (32 patients). Follow-up was done up to three years. Combined treatment permitted reduction of the levodopa dosage by 39%. As assessed by improvement of symptoms of Parkinson's syndrome in patients with a minimum treatment period of 1 or 3 years combined treatment was shown to be superior to monotherapy.
D000368:Aged; D001545:Benserazide / Q000009:adverse effects / Q000627:therapeutic use; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D011897:Random Allocation; D013997:Time Factors
D001971:Bromocriptine; D007980:Levodopa; D001545:Benserazide
Kombinationsbehandlung früher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Ergebnisse einer multizentrischen Studie.